AmericanHHM
BD - Earth day 2024

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

Wednesday, May 24, 2023

Camurus today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended release injection for subcutaneous (SC) use, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder (OUD), in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product. Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.1 The product will be marketed in the US by Camurus' licensee Braeburn.

OUD is a complex and potentially life-threatening condition with a significant negative impact on the individual, their families, and society. The US prevalence of OUD is estimated to be between 6–7 million people2; of these approximately 3 million are diagnosed with OUD, with about half receiving medical treatment.3,4

"The opioid crisis continues to weigh heavily on US society with approximately 80,000 opioid overdose deaths annually.5 Brixadi offers US patients and healthcare professionals a new and effective treatment option for opioid use disorder, with both weekly and monthly dosing to meet patient's individual treatment needs," says Dr. Fredrik Tiberg, President & CEO of Camurus. "Based on the success of Buvidal in Europe, Australia and other territories, we see a significant opportunity for Brixadi in the US," he continues.

The FDA approval of Brixadi was based on an extensive clinical program with a randomized, active-controlled Phase 3 trial of CAM2038 against standard treatment with daily sublingual buprenorphine/naloxone (SL BPN).6 The pivotal trial met the primary endpoint of non-inferiority for responder rate (p<0.001) and the first secondary endpoint of superiority for the reduction of overall illicit use from week 4 through week 24 (p=0.004), measured by the cumulative distribution function of the percentage of negative opioid assessments. In addition, the product demonstrated rapid and prolonged reduction of withdrawal and cravings, 6-8 and blockade of opioid drug liking.8 The safety profile of Brixadi was consistent with the known safety profile of SL BPN except for mild to moderate injection site reactions.1,6,7

Brixadi is formulated using Camurus' FluidCrystal® injection depot technology. The product is administered subcutaneously by a healthcare professional as a small volume injection (0.16-0.64 mL) in the buttock, thigh, stomach, or upper arm. Brixadi does not require refrigeration.


Source: prnewswire.co.uk

Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit